Synthetic Lethality Patents

Synthetic lethality patents cover synthetic-lethal-target innovations; inhibitor composition-of-matter; biomarker-stratification innovations; and discovery-platform innovations — with IP held by PARP-inhibitor pioneers and next-generation DNA-damage-response and metabolic-synthetic-lethality companies. WHAT IS SYNTHETIC LETHALITY: two genes are 'synthetically lethal' if losing BOTH kills the cell but losing EITHER alone is tolerated — so if a cancer already has a mutation in gene A (e.g. BRCA, lost in the tumor but intact in normal cells), a drug inhibiting its synthetic-lethal partner gene B selectively kills the cancer while sparing normal cells (which still have gene A) — a powerful, tumor-selective targeting principle. MAJOR SYNTHETIC-LETHALITY PATENT HOLDERS: ASTRAZENECA (Lynparza/olaparib — the breakthrough PARP inhibitor exploiting PARP-BRCA synthetic lethality in BRCA-mutant ovarian/breast cancer), plus GSK (Zejula/niraparib), Pfizer (Talzenna/talazoparib), and Clovis (Rubraca/rucaparib) — the PARP class. NEXT-GENERATION: Repare Therapeutics (a synthetic-lethality discovery platform — WRN, POLQ, PKMYT1), IDEAYA Biosciences (MAT2A/PRMT5 for MTAP-deletion, Werner WRN), Novartis (WRN), Mirati/BMS and Amgen and Tango (PRMT5 / MTAP-deletion), Artios (POLQ polymerase-theta), Zentalis (WEE1), and ATR/DNA-PK inhibitor holders. PARP-BRCA, DNA-damage-response targets, and metabolic synthetic lethality (MTAP/PRMT5, WRN/MSI) are the core synthetic-lethality patent domains.

Synthetic-lethal-target identification innovations; inhibitor composition-of-matter; DNA-damage-response target innovations; and metabolic-synthetic-lethality innovations represent core synthetic-lethality patent domains — and both the inhibitor molecule AND the target-context method are patentable. INHIBITOR COMPOSITION-OF-MATTER PATENTS: the specific small-molecule inhibitor of the synthetic-lethal target (PARP, WRN helicase, POLQ, PRMT5, MAT2A, ATR, WEE1, DNA-PK, USP1, PKMYT1) — claimed as a new chemical entity with the durable ~20-year composition-of-matter protection (olaparib, and next-gen inhibitors, are patented molecules). DNA-DAMAGE-RESPONSE (DDR) TARGET PATENTS: inhibitors of DDR proteins that become essential when a tumor's DNA-repair is already compromised — PARP (single-strand-break repair, synthetic-lethal with BRCA/homologous-recombination deficiency), ATR/WEE1/CHK1 (replication-stress checkpoints), POLQ (polymerase-theta, microhomology-mediated end joining — synthetic-lethal with HR deficiency, a hot target), and DNA-PK. METABOLIC SYNTHETIC-LETHALITY PATENTS: exploiting non-DNA-repair vulnerabilities — MTAP-deletion (a common co-deletion with CDKN2A creating dependence on PRMT5/MAT2A — Ideaya/Mirati/Amgen), and WRN (Werner helicase, synthetic-lethal in microsatellite-instability-high MSI cancers — a major recent target). TARGET-PAIR PATENTS: the specific synthetic-lethal relationship and the inhibitor-in-context. The inhibitor (composition-of-matter) against a validated synthetic-lethal target — especially the next-generation WRN/POLQ/PRMT5 targets — is the highest-value synthetic-lethality IP.

Biomarker and patient-stratification innovations; functional-genomics discovery innovations; combination and resistance innovations; and method-of-treatment innovations represent additional synthetic-lethality patent domains — and identifying which patients have the enabling mutation (the biomarker) is central to synthetic lethality. BIOMARKER / STRATIFICATION PATENTS: methods of treating a biomarker-DEFINED patient population — the synthetic-lethal partner mutation that makes the drug work (BRCA1/2 mutation or HR-deficiency 'HRD score' for PARP; MTAP-deletion for PRMT5; MSI-high for WRN; specific alterations for others) — these METHOD-OF-TREATMENT-in-a-defined-population claims are valuable and more §101-durable than bare correlations (claiming a treatment, not just a diagnostic), and the companion-diagnostic biomarker is a parallel asset. DISCOVERY-PLATFORM PATENTS: functional-genomics CRISPR/RNAi screens that systematically identify synthetic-lethal gene pairs across cancer genotypes (Repare's platform, KSQ, and others), the screening method, and the resulting validated target-context pairs — these discovery methods are most defensible tied to specific assays/results (a bare 'find synthetic-lethal pairs by screening' claim risks §101). COMBINATION / RESISTANCE PATENTS: combinations (PARP + ATR, PARP + immunotherapy) to deepen response and overcome resistance, and resistance-mechanism coverage. Biomarker-stratified method-of-treatment claims and validated novel synthetic-lethal target-context pairs are the highest-value synthetic-lethality IP because they define the durable franchise around a target.

Synthetic lethality startup IP strategy must navigate AstraZeneca/GSK/Pfizer PARP estates (the validated, mature class), next-generation target estates (Repare/Ideaya/Novartis WRN, Ideaya/Mirati/Amgen PRMT5/MTAP, Artios/Repare POLQ), foundational synthetic-lethality and DDR academic prior art, a §101-light landscape for the inhibitor molecules (concrete chemistry) but §101-sensitive for pure biomarker/screening methods, and a landscape where the inhibitor, the biomarker-defined population, and the validated target choice are the durable assets; understand that PARP-BRCA is crowded/mature, that the open, high-value frontiers are next-generation targets (WRN/MSI, PRMT5/MTAP-deletion, POLQ, PKMYT1) and that for each the inhibitor (composition-of-matter) plus the biomarker-stratified method-of-treatment are the core IP; identify whitespace in novel synthetic-lethal targets, best-in-class inhibitors, combinations, and biomarker stratification. SYNTHETIC-LETHALITY STARTUP IP STRATEGY: THE INHIBITOR (COMPOSITION-OF-MATTER) PLUS THE BIOMARKER-STRATIFIED TREATMENT ARE THE IP: patent the specific inhibitor molecule (durable ~20-year composition-of-matter) AND the method of treating the biomarker-defined population — together they define the franchise; NEXT-GENERATION TARGETS (WRN, PRMT5/MTAP, POLQ) ARE HIGHEST-VALUE WHITESPACE — PARP IS MATURE: PARP-BRCA is validated but crowded; the open opportunities are WRN (MSI-high cancers), PRMT5/MAT2A (MTAP-deleted tumors), POLQ (HR-deficient), and PKMYT1/USP1 — a best-in-class inhibitor of a hot synthetic-lethal target is the prize; BIOMARKER STRATIFICATION IS THE FRANCHISE-DEFINER (AND §101-DURABLE AS METHOD-OF-TREATMENT): claim the treatment in the biomarker-defined population (BRCA/HRD, MTAP-deletion, MSI), not a bare diagnostic — and develop the companion diagnostic; DISCOVERY PLATFORMS ARE VALUABLE BUT §101-SENSITIVE: CRISPR functional-genomics screens that find synthetic-lethal pairs are a real engine — patent the validated target-context results and tie screening methods to specific assays; COMBINATIONS DEEPEN RESPONSE AND OVERCOME RESISTANCE: PARP/ATR, target + immunotherapy combinations are patentable method IP; WHEN TO PATENT: NOVEL INHIBITOR/TARGET WITH MEASURED ACTIVITY: file composition-of-matter once an inhibitor shows measured results (target potency/selectivity + synthetic-lethal-context dependence + efficacy in biomarker-defined models + tolerability) — measured potency, biomarker-context selectivity, and efficacy in the defined population are the critical synthetic-lethality IP metrics; KEY FTO CHECKLIST: AstraZeneca olaparib + GSK/Pfizer/Clovis PARP-BRCA/HRD; Repare/Ideaya/Novartis WRN Werner-helicase MSI; Ideaya/Mirati/Amgen/Tango PRMT5/MAT2A MTAP-deletion; Artios/Repare POLQ polymerase-theta HR-deficiency; ATR/WEE1/CHK1/DNA-PK/USP1/PKMYT1 DDR; inhibitor composition-of-matter; biomarker-stratified method-of-treatment (BRCA/HRD/MTAP/MSI companion diagnostic); CRISPR functional-genomics synthetic-lethal screen (§101-tied); PARP+ATR/immunotherapy combination; resistance coverage.